Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of chronic obstructive pulmonary disease Vol. 19; pp. 11 - 16
Main Authors:	Faruqi, Muhammad Asad, Khan, Malik M Khurram S, Mannino, David M
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01-01-2024 Dove Dove Medical Press
Subjects:	Bronchi Care and treatment chronic obstructive pulmonary disease Development and progression Humans Isoquinolines Lung diseases Medical colleges phospohodiesterase inhibitor Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - drug therapy Pyrimidinones Review Roflumilast therapy Tiotropium United States United States phosphodiesterase inhibitor therapy chronic obstructive pulmonary disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1178-2005 1176-9106 1178-2005
DOI:	10.2147/COPD.S385811